Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-394136 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-394136 | DRUG | Oral Solution, Oral, 100 mg, Single dose, 1 day. |
| Placebo | DRUG | Oral Solution, Oral, 0 mg, Single dose, 1 day. |
Inclusion Criteria: * Patients with dual-chamber pacemakers or defibrillators Exclusion Criteria: * Recent acute ischemic events * Recent atrial or ventricular arrhythmias * Uncompensated heart failure * Amiodarone use within last year * Women of childbearing potential * QTc \<430 msec males * QT...
BMS-394136 is an investigational small molecule being developed for heart diseases. It is being studied for its electrophysiologic effects on the atrium and ventricle in patients with dual-chamber pacemakers or defibrillators. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
BMS-394136 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's safety and effects in patients with heart diseases.
BMS-394136 is in Phase 1 clinical development. A Phase 1 study has been completed, which assessed the drug's electrophysiologic effects on the atrium and ventricle in patients with dual-chamber pacemakers or defibrillators. The drug is investigational and has not been approved by the FDA.
BMS-394136 has one completed clinical trial registered as NCT00162448. This Phase 1 study assessed the electrophysiologic effects of the drug on the atrium and ventricle in patients with dual-chamber pacemakers or defibrillators. The trial enrolled 36 participants in the United States and was placebo-controlled and double-blind.
No alternative names for BMS-394136 have been disclosed. The drug is identified by its development code BMS-394136 and is being studied by Bristol-Myers Squibb. It is a small molecule intended for the treatment of heart diseases, currently in early-stage clinical investigation.